Livatag doxorubicin Transdrug: Phase III ongoing

BioAlliance said an independent DSMB for a second time recommended continuation of the open-label, international Phase III ReLive trial evaluating 20 and 30 mg/m 2 IV Livatag in about 400 patients with HCC resistant or intolerant to sorafenib based on safety data. ReLive has enrolled about 40 patients. The DSMB, which meets every 6 months and/or after the recruitment of 75 patients, recommended continuation of ReLive last November (see BioCentury, Dec. 24, 2012). ...